Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
TPM3-ALK, Active(A19-19DG)

TPM3-ALK, Active(A19-19DG)

  • $259.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human fusion protein TPM3 (1-258)-ALK (1058-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :1-258 (TPM3) - 1058-end (ALK)

Genbank Number :NM_152263

Genbank Number 2 :NM_004304

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay

Molecular Weight :~125 kDa

Gene Aliases :TPM3: CAPM1; CFTD; hscp30; NEM1; TM-5; TM3; TM30; TM30nm; TM5; TPMsk3; OK/SW-cl.5
ALK: ALK (Ki-1), CD246, NBLST3, TFG/ALK

Scientific Background :ALK or CD246 is a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. CD246 plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. ALK-positive neoplasms represent a distinct entity because the morphology of the tumors is often neither anaplastic nor large cell and the tumors should be referred to as ALK lymphomas (1). CD246 has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. CD246 act as a driver of inflammation. TPM3-ALK fusion oncogene sufficiently induces lymphoma/leukemia disorders (2).

References :
1. Benharroch, D.et.al: ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91: 2076-2084, 1998.

2. Giuriato S. et al: Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood. 2010 May 20; 115(20): 4061-70.

Product Sheets (By Lot #) :

A1218-2.pdf

Research Areas :Cancer, Cancer